Macquarie Group
HOWL icon

Macquarie Group’s Werewolf Therapeutics HOWL Stock Holding History

Macquarie Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-940
Closed -$6 – 2001
2024
Q1 		$6 Buy
+940
New +$5.48K ﹤0.01% 1769

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group's HOWL Position: Q2 2024 in Review

Macquarie Group sold out of Werewolf Therapeutics (HOWL) in Q2 2024, closing a stake of 940 shares — an estimated $6 sold.

Macquarie Group first reported a position in HOWL in Q1 2024 and held it in 1 quarter. The position peaked at $6 in Q1 2024. 71 funds tracked by Wall St. Rank hold HOWL as of Q2 2024.

  • Macquarie Group reported no remaining Werewolf Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 940 Werewolf Therapeutics shares in Q2 2024, an estimated $6.
  • Macquarie Group first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Werewolf Therapeutics position peaked at $6 in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.